Page last updated: 2024-08-23

etoposide and Hypercoagulability

etoposide has been researched along with Hypercoagulability in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (50.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M	1
Annaloro, C; Deliliers, GL; Ibatici, A; Nicolini, A; Pozzoli, E; Robbiolo, L; Salerno, F	1
Becker, AT; Gruppo, RA; Harris, RE; Hashmi, R; Morris, CL; Morris, JD; Sambrano, JE	1
Bairey, O; Blickstein, D; Epstein, O; Gabbay, U; Lahav, J; Prokocimer, M; Shaklai, M; Stark, P	1
Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B	1
Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M	1

Trials

1 trial(s) available for etoposide and Hypercoagulability

Article	Year
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3 Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Factor V; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Life Tables; Male; Middle Aged; Multiple Myeloma; Risk; Thalidomide; Thrombophilia; Venous Thrombosis; Vincristine	2002

Article

Year

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3

Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Factor V; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Life Tables; Male; Middle Aged; Multiple Myeloma; Risk; Thalidomide; Thrombophilia; Venous Thrombosis; Vincristine

2002

Other Studies

5 other study(ies) available for etoposide and Hypercoagulability

Article	Year
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5 Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; Etoposide; Factor V; Follow-Up Studies; Humans; Hyperhomocysteinemia; Multiple Myeloma; Prednisone; Pulmonary Embolism; Retrospective Studies; Thalidomide; Thrombophilia; Venous Thrombosis	2009
Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation. Leukemia & lymphoma, 2004, Volume: 45, Issue:7 Topics: Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hemodynamics; Hepatic Veno-Occlusive Disease; Humans; Jugular Veins; Lymphoma, Large-Cell, Anaplastic; Male; Peripheral Blood Stem Cell Transplantation; Portasystemic Shunt, Surgical; Remission Induction; Thrombophilia; Transplantation Conditioning; Transplantation, Autologous	2004
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone marrow transplantation, 1997, Volume: 20, Issue:10 Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Life Tables; Male; Multiple Organ Failure; Neoplasms; Severity of Illness Index; Survival Analysis; Thrombophilia; Transplantation Conditioning; Treatment Outcome	1997
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients. Hematological oncology, 1997, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Partial Thromboplastin Time; Plasminogen; Prednisone; Procarbazine; Protein C; Protein S; Thrombophilia; Time Factors; Vinblastine; Vincristine	1997
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease. Leukemia, 1999, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin	1999